Center-Authored Papers

Filters: Author is LeBlanc, Michael  [Clear All Filters]
2003
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract
2005
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.  2005.  New treatment options have changed the survival of patients with follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(33):8447-52. Abstract
2006
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
2008
Goldman B, LeBlanc M, Crowley J.  2008.  Interim futility analysis with intermediate endpoints.. Clinical trials (London, England). 5(1):14-22. Abstract
Kooperberg C, LeBlanc M.  2008.  Increasing the power of identifying gene x gene interactions in genome-wide association studies.. Genetic epidemiology. 32(3):255-63. Abstract
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
Hoering A, LeBlanc M, Crowley J.  2008.  Randomized phase III clinical trial designs for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14):4358-67. Abstract
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI.  2008.  Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.. Transplantation. 86(2):215-22. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
2009
Kooperberg C, LeBlanc M, Dai JY, Rajapakse I.  2009.  Structures and Assumptions: Strategies to Harness Gene × Gene and Gene × Environment Interactions in GWAS.. Statistical science : a review journal of the Institute of Mathematical Statistics. 24(4):472-488. Abstract
Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI.  2009.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(1):114-9. Abstract
LeBlanc M, Kooperberg C.  2009.  Adaptively weighted association statistics.. Genetic epidemiology. 33(5):442-52. Abstract
LeBlanc M, Rankin C, Crowley J.  2009.  Multiple Histology Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13):4256-62. Abstract
Dai JY, LeBlanc M, Kooperberg C.  2009.  Semiparametric estimation exploiting covariate independence in two-phase randomized trials.. Biometrics. 65(1):178-87. Abstract
Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D.  2009.  Randomized phase II designs.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(6):1883-90. Abstract
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract
Dai JY, LeBlanc M, Smith NL, Psaty B, Kooperberg C.  2009.  SHARE: an adaptive algorithm to select the most informative set of SNPs for candidate genetic association.. Biostatistics (Oxford, England). 10(4):680-93. Abstract
Yoo GH, Moon J, LeBlanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J et al..  2009.  A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of otolaryngology--head & neck surgery. 135(9):869-74. Abstract
2010
LeBlanc M, Kooperberg C.  2010.  Boosting predictions of treatment success.. Proceedings of the National Academy of Sciences of the United States of America. 107(31):13559-60.
Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM.  2010.  Notch signaling is not essential in sonic hedgehog-activated medulloblastoma.. Oncogene. 29(26):3865-72. Abstract
Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG.  2010.  Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(20):3330-5. Abstract
Sweetenham JW, Goldman B, LeBlanc M, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM et al..  2010.  Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 21(6):1196-202. Abstract
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
Kooperberg C, LeBlanc M, Obenchain V.  2010.  Risk prediction using genome-wide association studies.. Genetic epidemiology. 34(7):643-52. Abstract